Business Description
Oragenics Inc
NAICS : 325412
SIC : 2834
ISIN : US6840235005
Description
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.06 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.1 | |||||
| 3-Year EPS without NRI Growth Rate | 31.3 | |||||
| 3-Year FCF Growth Rate | 41.1 | |||||
| 3-Year Book Growth Rate | -56.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.02 | |||||
| 9-Day RSI | 38.77 | |||||
| 14-Day RSI | 43.34 | |||||
| 6-1 Month Momentum % | -69.99 | |||||
| 12-1 Month Momentum % | -94.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.93 | |||||
| Cash Ratio | 1.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.3 | |||||
| Shareholder Yield % | -151.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -598 | |||||
| ROA % | -410.6 | |||||
| ROIC % | -1493.58 | |||||
| 3-Year ROIIC % | 3416.07 | |||||
| ROC (Joel Greenblatt) % | -2689.07 | |||||
| ROCE % | -597.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.17 | |||||
| Price-to-Tangible-Book | 2.17 | |||||
| EV-to-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.16 | |||||
| EV-to-FCF | -0.43 | |||||
| Price-to-Net-Current-Asset-Value | 8.58 | |||||
| Price-to-Net-Cash | 3.12 | |||||
| Earnings Yield (Greenblatt) % | -625 | |||||
| FCF Yield % | -177.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oragenics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -7.07 | ||
| Beta | 2.84 | ||
| Volatility % | 164.96 | ||
| 14-Day RSI | 43.34 | ||
| 14-Day ATR ($) | 0.02055 | ||
| 20-Day SMA ($) | 0.366725 | ||
| 12-1 Month Momentum % | -94.59 | ||
| 52-Week Range ($) | 0.2648 - 6.4822 | ||
| Shares Outstanding (Mil) | 12.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oragenics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oragenics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oragenics Inc Frequently Asked Questions
What is Oragenics Inc(LTS:0A64)'s stock price today?
The current price of LTS:0A64 is $0.33. The 52 week high of LTS:0A64 is $6.48 and 52 week low is $0.26.
When is next earnings date of Oragenics Inc(LTS:0A64)?
The next earnings date of Oragenics Inc(LTS:0A64) is 2025-02-13 Est..
Does Oragenics Inc(LTS:0A64) pay dividends? If so, how much?
Oragenics Inc(LTS:0A64) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers